Download PDF
Hamostaseologie 2020; 40(01): 074-083
DOI: 10.1055/s-0040-1701476
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Oral Anticoagulation in the Elderly and Frail

Rupert M. Bauersachs
1   Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany
2   Center for Thrombosis and Hemostasis, University Medical Center, Mainz, Germany
,
Joerg Herold
1   Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany
› Author Affiliations
Further Information

Publication History

11 September 2019

10 December 2019

Publication Date:
30 January 2020 (online)

Also available at
   Permissions and Reprints

Abstract

The proportion of elderly patients will increase substantially over the next decades, and both atrial fibrillation (AF) and venous thromboembolism (VTE) are more common in the elderly. Age is a risk factor not only for stroke and thromboembolism but also for bleeding, particularly in frail patients, in whom numerous pathophysiological changes occur that alter drug kinetics and toxicity of standard doses of oral anticoagulants (OACs). AF trials showed that the relative benefits of direct OACs (DOACs) also applied to elderly patients, and due to their higher risk this translates into a higher absolute risk reduction compared with vitamin K antagonists, suggesting that DOACs are the better choice. All DOACs—at varying extent—are eliminated via the kidney and it is crucial to evaluate renal function at initiation and during follow-up, especially for dabigatran. The fear of falls is a common reason against OAC. However, there is still a benefit with OAC, particularly with DOACs given the lower risk of intracranial hemorrhage. Polypharmacy represents a common challenge, nevertheless DOACs and warfarin were classified as beneficial. Nonetheless, attempts should be undertaken to reduce comedication, and drug–drug interactions should be assessed. Coadministration of platelet inhibitors increases bleeding risk and should be avoided. In conclusion, elderly and frail patients requiring anticoagulation for AF or VTE are at higher risk of adverse outcomes, but also have a higher absolute benefit from OAC. Important practical aspects to improve efficacy and safety in this challenging population are summarized in this overview.

Keywords

anticoagulation - elderly - frail - atrial fibrillation - venous thromboembolism
 

  • References

  • 1 Bevölkerung in absoluten Zahlen, Anteile der Altersgruppen in Prozent, 1960 bis 2050 Statistisches Bundesamt: Lange Reihen: Bevölkerung nach Altersgruppen, 13. koordinierte Bevölkerungsvorausberechnung: Bevölkerung Deutschlands bis 2060: Bundeszentrale für Politische Bildung; [Available from: Available at: https://www.bpb.de/nachschlagen/zahlen-und-fakten/soziale-situation-in-deutschland/61541/altersstruktur
    PubMed
  • 2 Ergebnisse der 14. koordinierten Bevölkerungsvorausberechnung: Statistisches Bundesamt. Available at: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Bevoelkerung/Bevoelkerungsvorausberechnung/Tabellen/variante-1-2-3-altersgruppen.html;jsessionid=452C6718CB5A674FB003FFF71486C2B9.internet712
    PubMed
  • 3 Rosendaal FR, VAN Hylckama Vlieg A, Doggen CJ. Venous thrombosis in the elderly. J Thromb Haemost 2007; 5 (Suppl. 01) 310-317
    CrossrefPubMedGoogle Scholar
  • 4 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5 (04) 692-699
    CrossrefPubMedGoogle Scholar
  • 5 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
    PubMedGoogle Scholar
  • 6 Go AS, Hylek EM, Phillips KA. , et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285 (18) 2370-2375
    CrossrefPubMedGoogle Scholar
  • 7 Kirchhof P, Benussi S, Kotecha D. , et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
    CrossrefPubMedGoogle Scholar
  • 8 Cruz-Jentoft AJ, Baeyens JP, Bauer JM. , et al; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39 (04) 412-423
    CrossrefPubMedGoogle Scholar
  • 9 Lacas A, Rockwood K. Frailty in primary care: a review of its conceptualization and implications for practice. BMC Med 2012; 10: 4
    CrossrefPubMedGoogle Scholar
  • 10 Gobbens RJ, Luijkx KG, Wijnen-Sponselee MT, Schols JM. Towards an integral conceptual model of frailty. J Nutr Health Aging 2010; 14 (03) 175-181
    CrossrefPubMedGoogle Scholar
  • 11 Fried LP, Tangen CM, Walston J. , et al; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56 (03) M146-M156
    CrossrefPubMedGoogle Scholar
  • 12 Bauersachs RM. Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups. Eur J Intern Med 2014; 25 (07) 600-606
    CrossrefPubMedGoogle Scholar
  • 13 Bauersachs RM. Use of anticoagulants in elderly patients. Thromb Res 2012; 129 (02) 107-115
    CrossrefPubMedGoogle Scholar
  • 14 Prins MH, Lensing AW, Bauersachs R. , et al; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11 (01) 21
    CrossrefPubMedGoogle Scholar
  • 15 Oqab Z, Pournazari P, Sheldon RS. What is the impact of frailty on prescription of anticoagulation in elderly patients with atrial fibrillation? A systematic review and meta-analysis. J Atr Fibrillation 2018; 10 (06) 1870
    PubMedGoogle Scholar
  • 16 López-Jiménez L, Montero M, González-Fajardo JA. , et al; RIETE Investigators. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica 2006; 91 (08) 1046-1051
    PubMedGoogle Scholar
  • 17 Trujillo-Santos J, Schellong S, Falga C. , et al; RIETE Investigators. Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function. Am J Med 2013; 126 (05) 425.e1-434.e1
    PubMedGoogle Scholar
  • 18 Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57 (01) 6-14
    CrossrefPubMedGoogle Scholar
  • 19 Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005; 127 (06) 2049-2056
    CrossrefPubMedGoogle Scholar
  • 20 Samama MM. Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment. Drugs Aging 2011; 28 (03) 177-193
    CrossrefPubMedGoogle Scholar
  • 21 Silverstein RL, Bauer KA, Cushman M, Esmon CT, Ershler WB, Tracy RP. Venous thrombosis in the elderly: more questions than answers. Blood 2007; 110 (09) 3097-3101
    PubMedGoogle Scholar
  • 22 Fohtung RB, Novak E, Rich MW. Effect of new oral anticoagulants on prescribing practices for atrial fibrillation in older adults. J Am Geriatr Soc 2017; 65 (11) 2405-2412
    CrossrefPubMedGoogle Scholar
  • 23 Bai Y, Guo SD, Deng H. , et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. Age Ageing 2018; 47 (01) 9-17
    PubMedGoogle Scholar
  • 24 Ruff CT, Giugliano RP, Braunwald E. , et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921): 955-962
    CrossrefPubMedGoogle Scholar
  • 25 Kato ET, Giugliano RP, Ruff CT. , et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 2016; 5 (05) e003432
    PubMedGoogle Scholar
  • 26 Patti G, Pecen L, Lucerna M. , et al. Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med 2019; 132 (06) 749.e5-757.e5
    PubMedGoogle Scholar
  • 27 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 28 Bauersachs RM, Lensing AW, Prins MH. , et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J 2014; 12: 25
    CrossrefPubMedGoogle Scholar
  • 29 Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 2015; 132 (03) 194-204
    CrossrefPubMedGoogle Scholar
  • 30 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 31 Group IGOCW. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150
    PubMedGoogle Scholar
  • 32 Erratum Regarding. Erratum regarding “KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis” (Am J Kidney Dis. 2013;62[3]:403-441). Am J Kidney Dis 2017; 69 (03) 485
    CrossrefPubMedGoogle Scholar
  • 33 Sarnak MJ, Bloom R, Muntner P. , et al. KDOQI US commentary on the 2013 KDIGO clinical practice guideline for lipid management in CKD. Am J Kidney Dis 2015; 65 (03) 354-366
    CrossrefPubMedGoogle Scholar
  • 34 Steffel J, Verhamme P, Potpara TS. , et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
    CrossrefPubMedGoogle Scholar
  • 35 Soliman EZ, Prineas RJ, Go AS. , et al; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159 (06) 1102-1107
    CrossrefPubMedGoogle Scholar
  • 36 Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 2010; 341: c4249
    CrossrefPubMedGoogle Scholar
  • 37 Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol 2010; 56 (11) 827-837
    CrossrefPubMedGoogle Scholar
  • 38 Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011; 57 (12) 1339-1348
    CrossrefPubMedGoogle Scholar
  • 39 Monreal M, Falgá C, Valle R. , et al; RIETE Investigators. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119 (12) 1073-1079
    CrossrefPubMedGoogle Scholar
  • 40 Olesen JB, Lip GY, Kamper AL. , et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367 (07) 625-635
    CrossrefPubMedGoogle Scholar
  • 41 Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 2011; 57 (02) 173-180
    CrossrefPubMedGoogle Scholar
  • 42 Gangireddy C, Rectenwald JR, Upchurch GR. , et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007; 45 (02) 335-341 , discussion 341–342
    CrossrefPubMedGoogle Scholar
  • 43 Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 2010; 8 (10) 2105-2112
    CrossrefPubMedGoogle Scholar
  • 44 Cook LM, Kahn SR, Goodwin J, Kovacs MJ. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost 2007; 5 (05) 937-941
    CrossrefPubMedGoogle Scholar
  • 45 Camm AJ, Kirchhof P, Lip GY. , et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19) 2369-2429
    CrossrefPubMedGoogle Scholar
  • 46 Gage BF, Yan Y, Milligan PE. , et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151 (03) 713-719
    CrossrefPubMedGoogle Scholar
  • 47 Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008; 4 (08) 1065-1074
    CrossrefPubMedGoogle Scholar
  • 48 Limdi NA, Beasley TM, Baird MF. , et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20 (04) 912-921
    CrossrefPubMedGoogle Scholar
  • 49 Kleinow ME, Garwood CL, Clemente JL, Whittaker P. Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J Manag Care Pharm 2011; 17 (07) 523-530
    Google Scholar
  • 50 Zou R, Tao J, Shi W. , et al. Meta-analysis of safety and efficacy for direct oral anticoagulation treatment of non-valvular atrial fibrillation in relation to renal function. Thromb Res 2017; 160: 41-50
    CrossrefPubMedGoogle Scholar
  • 51 Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017; 69 (23) 2779-2790
    CrossrefPubMedGoogle Scholar
  • 52 Donzé J, Clair C, Hug B. , et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012; 125 (08) 773-778
    CrossrefPubMedGoogle Scholar
  • 53 Tiedemann A, Lord SR, Sherrington C. The development and validation of a brief performance-based fall risk assessment tool for use in primary care. J Gerontol A Biol Sci Med Sci 2010; 65 (08) 896-903
    PubMedGoogle Scholar
  • 54 Rubenstein LZ. Falls in older people: epidemiology, risk factors and strategies for prevention. Age Ageing 2006; 35 (Suppl. 02) ii37-ii41
    CrossrefPubMedGoogle Scholar
  • 55 Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159 (07) 677-685
    CrossrefPubMedGoogle Scholar
  • 56 Bhattacharya B, Maung A, Schuster K, Davis KA. The older they are the harder they fall: injury patterns and outcomes by age after ground level falls. Injury 2016; 47 (09) 1955-1959
    CrossrefPubMedGoogle Scholar
  • 57 Tricco AC, Thomas SM, Veroniki AA. , et al. Comparisons of interventions for preventing falls in older adults: a systematic review and meta-analysis. JAMA 2017; 318 (17) 1687-1699
    CrossrefPubMedGoogle Scholar
  • 58 Steffel J, Giugliano RP, Braunwald E. , et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll Cardiol 2016; 68 (11) 1169-1178
    CrossrefPubMedGoogle Scholar
  • 59 Rao MP, Vinereanu D, Wojdyla DM. , et al; Apixaban for Reduction in Stroke Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. Am J Med 2018; 131 (03) 269-275.e2
    CrossrefPubMedGoogle Scholar
  • 60 Friberg L, Andersson T, Rosenqvist M. Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation. Eur Heart J 2019; 40 (28) 2327-2335
    CrossrefPubMedGoogle Scholar
  • 61 Jaspers Focks J, Brouwer MA, Wojdyla DM. , et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ 2016; 353: i2868
    PubMedGoogle Scholar
  • 62 Wehling M, Collins R, Gil VM. , et al. Appropriateness of oral anticoagulants for the long-term treatment of atrial fibrillation in older people: results of an evidence-based review and international consensus validation process (OAC-FORTA 2016). Drugs Aging 2017; 34 (07) 499-507
    CrossrefPubMedGoogle Scholar
  • 63 Pazan F, Weiss C, Wehling M. ; FORTA. The FORTA (Fit fOR The Aged) list 2015: update of a validated clinical tool for improved pharmacotherapy in the elderly. Drugs Aging 2016; 33 (06) 447-449
    CrossrefPubMedGoogle Scholar
  • 64 Pazan F, Weiss C, Wehling M. ; FORTA. Correction to: the EURO-FORTA (Fit fOR The Aged) list: international consensus validation of a clinical tool for improved drug treatment in older people. Drugs Aging 2018; 35 (07) 677
    CrossrefPubMedGoogle Scholar
  • 65 Pazan F, Weiss C, Wehling M. ; FORTA. The EURO-FORTA (Fit fOR The Aged) list: international consensus validation of a clinical tool for improved drug treatment in older people. Drugs Aging 2018; 35 (01) 61-71
    CrossrefPubMedGoogle Scholar
  • 66 Samuel NG, Seifert CF. Risk of bleeding in patients on full-dose enoxaparin with venous thromboembolism and selective serotonin reuptake inhibitors. Ann Pharmacother 2017; 51 (03) 226-231
    CrossrefPubMedGoogle Scholar
  • 67 Roffi M, Patrono C, Collet JP. , et al; ESC Scientific Document Group. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (03) 267-315
    CrossrefPubMedGoogle Scholar